Orphan drug development in alpha-1 antitypsin deficiency
Alpha-1 antitrypsin deficiency (AATD, OMIM #613490) is a rare metabolic disorder affecting lungs and liver. The purpose of this study is to assess the impact of the US orphan drug act on AATD by providing a quantitative clinical-regulatory insight into the status of FDA orphan drug approvals and des...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15. September 2022
|
| In: |
Scientific reports
Year: 2022, Jahrgang: 12, Pages: 1-8 |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-022-19707-2 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41598-022-19707-2 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41598-022-19707-2 
|
| Verfasserangaben: | Franziska C. Trudzinski, Maria Ada Presotto, Emanuel Buck, Felix J. F. Herth & Markus Ries |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1816915750 | ||
| 003 | DE-627 | ||
| 005 | 20240417193551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220919s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-022-19707-2 |2 doi | |
| 035 | |a (DE-627)1816915750 | ||
| 035 | |a (DE-599)KXP1816915750 | ||
| 035 | |a (OCoLC)1361696450 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Trudzinski, Franziska |d 1976- |e VerfasserIn |0 (DE-588)1145072836 |0 (DE-627)100530047X |0 (DE-576)495615579 |4 aut | |
| 245 | 1 | 0 | |a Orphan drug development in alpha-1 antitypsin deficiency |c Franziska C. Trudzinski, Maria Ada Presotto, Emanuel Buck, Felix J. F. Herth & Markus Ries |
| 264 | 1 | |c 15. September 2022 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.09.2022 | ||
| 520 | |a Alpha-1 antitrypsin deficiency (AATD, OMIM #613490) is a rare metabolic disorder affecting lungs and liver. The purpose of this study is to assess the impact of the US orphan drug act on AATD by providing a quantitative clinical-regulatory insight into the status of FDA orphan drug approvals and designations for compounds intended to treat AATD. This is across-sectional analysis of the FDA database for orphan drug designations. Primary endpoint: orphan drug approvals. Secondary endpoint: orphan drug designations by the FDA. Close of database was 16 July 2021. STROBE criteria were respected. Primary outcome: one compound, alpha-1-proteinase inhibitor (human) was approved as an orphan drug in 1987 with market exclusivity until 1994. Secondary outcome: sixteen compounds received FDA orphan drug designation including protein, anti-inflammatory, mucolytic, gene, or cell therapy. Drug development activities in AATD were comparable to other rare conditions and led to the FDA-approval of one compound, based on a relatively simple technological platform. The current unmet medical need to be addressed are extrapulmonary manifestations, in this case the AATD-associated liver disease. Orphan drug development is actually focusing on (1) diversified recombinant AAT production platforms, and (2) innovative gene therapies, which may encompass a more holistic therapeutic approach. | ||
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Medical research | |
| 700 | 1 | |a Presotto, Maria Ada |d 1990- |e VerfasserIn |0 (DE-588)1258185156 |0 (DE-627)1804080160 |4 aut | |
| 700 | 1 | |a Buck, Emanuel |d 1992- |e VerfasserIn |0 (DE-588)1179725840 |0 (DE-627)1067424067 |0 (DE-576)518292290 |4 aut | |
| 700 | 1 | |a Herth, Felix |e VerfasserIn |0 (DE-588)1016095236 |0 (DE-627)705477568 |0 (DE-576)351509925 |4 aut | |
| 700 | 1 | |a Ries, Markus |d 1971- |e VerfasserIn |0 (DE-588)136385338 |0 (DE-627)582068479 |0 (DE-576)300993358 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d [London] : Springer Nature, 2011 |g 12(2022), Artikel-ID 15497, Seite 1-8 |h Online-Ressource |w (DE-627)663366712 |w (DE-600)2615211-3 |w (DE-576)346641179 |x 2045-2322 |7 nnas |a Orphan drug development in alpha-1 antitypsin deficiency |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g elocationid:15497 |g pages:1-8 |g extent:8 |a Orphan drug development in alpha-1 antitypsin deficiency |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41598-022-19707-2 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41598-022-19707-2 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220919 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 136385338 |a Ries, Markus |m 136385338:Ries, Markus |d 910000 |d 910500 |d 50000 |e 910000PR136385338 |e 910500PR136385338 |e 50000PR136385338 |k 0/910000/ |k 1/910000/910500/ |k 0/50000/ |p 5 |y j | ||
| 998 | |g 1016095236 |a Herth, Felix |m 1016095236:Herth, Felix |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1016095236 |e 950000PH1016095236 |e 950900PH1016095236 |e 50000PH1016095236 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 4 | ||
| 998 | |g 1179725840 |a Buck, Emanuel |m 1179725840:Buck, Emanuel |d 910000 |d 950000 |d 950900 |e 910000PB1179725840 |e 950000PB1179725840 |e 950900PB1179725840 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 3 | ||
| 998 | |g 1258185156 |a Presotto, Maria Ada |m 1258185156:Presotto, Maria Ada |d 910000 |d 950000 |d 950900 |e 910000PP1258185156 |e 950000PP1258185156 |e 950900PP1258185156 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 2 | ||
| 998 | |g 1145072836 |a Trudzinski, Franziska |m 1145072836:Trudzinski, Franziska |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PT1145072836 |e 950000PT1145072836 |e 950900PT1145072836 |e 50000PT1145072836 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1816915750 |e 4189924571 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1038/s41598-022-19707-2"],"eki":["1816915750"]},"name":{"displayForm":["Franziska C. Trudzinski, Maria Ada Presotto, Emanuel Buck, Felix J. F. Herth & Markus Ries"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"8 S."}],"origin":[{"dateIssuedDisp":"15. September 2022","dateIssuedKey":"2022"}],"language":["eng"],"title":[{"title":"Orphan drug development in alpha-1 antitypsin deficiency","title_sort":"Orphan drug development in alpha-1 antitypsin deficiency"}],"note":["Gesehen am 19.09.2022"],"relHost":[{"id":{"issn":["2045-2322"],"zdb":["2615211-3"],"eki":["663366712"]},"note":["Gesehen am 12.07.24"],"title":[{"title_sort":"Scientific reports","title":"Scientific reports"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1, article number 1 (2011)-"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"663366712","part":{"extent":"8","pages":"1-8","year":"2022","text":"12(2022), Artikel-ID 15497, Seite 1-8","volume":"12"},"origin":[{"dateIssuedKey":"2011","publisher":"Springer Nature ; Nature Publishing Group","dateIssuedDisp":"2011-","publisherPlace":"[London] ; London"}],"disp":"Orphan drug development in alpha-1 antitypsin deficiencyScientific reports"}],"recId":"1816915750","person":[{"given":"Franziska","role":"aut","family":"Trudzinski","display":"Trudzinski, Franziska"},{"given":"Maria Ada","role":"aut","family":"Presotto","display":"Presotto, Maria Ada"},{"role":"aut","given":"Emanuel","display":"Buck, Emanuel","family":"Buck"},{"role":"aut","given":"Felix","display":"Herth, Felix","family":"Herth"},{"family":"Ries","display":"Ries, Markus","given":"Markus","role":"aut"}]} | ||
| SRT | |a TRUDZINSKIORPHANDRUG1520 | ||